Last reviewed · How we verify
NCT05985239
Virtual Ileostomy Versus Diverting Ileostomy
trial testing VI in Rectal Cancer in 612 participants. Completed in 12 October 2024.
10 October 2024
Quick facts
| Lead sponsor | fan li |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 612 |
| Start date | 1 January 2023 |
| Primary completion | 10 October 2024 |
| Estimated completion | 12 October 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- VI — full drug profile →
- DI
Conditions studied
- Rectal Cancer — all drugs for Rectal Cancer →
Sponsor
fan li — full company profile →
Who can join
18 and older, any sex, with Rectal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aimed at comparing the Comprehensive Complication Index (CCI), readmission rates, postoperative hospitalization days, duration of bearing the stoma (months), hospitalization costs, the number of hospitalizations with virtual ileostomy versus conventional divertingileostomy after total mesorectal excision for rectal cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05985239
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of VI
Trials testing the same drug.
- NCT02164539 — Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component · Phase 2 · completed
- NCT01957163 — Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo P · Phase 3 · completed
- NCT01691547 — A Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of FluticasoneFuroate, Um · Phase 1 · completed
Other recruiting trials for Rectal Cancer
Currently open trials in the same condition.
- NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
- NCT07537998 — Antegrade Intestinal Fluid Reinfusion for Prevention of Low Anterior Resection Syndrome After Low Anterior Resection: a · Phase 2, PHASE3 · recruiting
- NCT07501845 — Registry Maastro Applicator · recruiting
- NCT07369531 — The Impact of Two-Stage Turnbull-Cutait Pull-Through Coloanal Anastomosis on Stoma-free Survival in Low Rectal Anal-pres · NA · recruiting
- NCT07505472 — Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Wit · Phase 2, PHASE3 · recruiting
Other fan li trials
Trials by the same sponsor.
- NCT06718543 — Neoadjuvant Short-Course Radiotherapy With or Without Chemotherapy and AK112 in Locally Advanced Rectal Cancer · Phase 2 · recruiting
- NCT06573424 — Tirellizumab+Anlotinib VS Anlotinib for MSS-type CRC · completed
- NCT06225609 — No Stoma VS Ghost Stoma in Patients Undergoing Total Mesorectal Excision for Rectal Cancer · NA · not yet recruiting
- NCT05833672 — Neoadjuvant Immunotherapy in Locally Advanced Colon Cancers · Phase 2 · unknown
- NCT05482529 — Integrative Omics Analysis for Colorectal Cancer and Metastasis · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05985239 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by fan li
- Last refreshed: 15 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05985239.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing